This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Hanlim Pharmaceutical Co., Ltd.. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: The Innovative Mind of Tae-Cheon Jeong: A Pioneer in Osteoporosis Treatment
Introduction: Tae-Cheon Jeong, a distinguished inventor based in Daegu, South Korea, has made significant strides in the field of pharmaceutical innovations. With a focus on improving patient care, his work addresses critical health issues such as osteoporosis, a condition that affects millions worldwide.
Latest Patents: Tae-Cheon Jeong holds one notable patent titled "2-cyanopyrimidin-4-yl carbamate or urea derivative or salt thereof, and pharmaceutical composition including same." This groundbreaking invention introduces a novel 2-cyanopyrimidin-4-yl carbamate or urea derivative, or pharmaceutically acceptable salt thereof, which has been shown to selectively inhibit cathepsin K. This mechanism of action has promising applications for the prevention and treatment of osteoporosis, potentially altering the landscape of therapy available to patients.
Career Highlights: Tae-Cheon Jeong is currently employed at Hanlim Pharmaceutical Co., Ltd., where he contributes his expertise in drug development and innovation. His dedication to research and progress in pharmaceuticals has made him a key player in the industry. The impact of his work not only enhances the company's portfolio but also provides hope for individuals affected by bone density diseases.
Collaborations: Throughout his career, Tae-Cheon Jeong has collaborated with esteemed colleagues, including Kyung-Hee Kim and Jung-Wook Chin. These partnerships foster a dynamic environment of shared ideas and innovations, enhancing the overall research efforts at Hanlim Pharmaceutical Co., Ltd. Together, they work towards creating effective solutions that address significant health challenges.
Conclusion: Tae-Cheon Jeong exemplifies the spirit of innovation in the pharmaceutical industry. His contributions, particularly in developing treatments for osteoporosis, underscore the importance of research and patenting in advancing healthcare solutions. As he continues his work at Hanlim Pharmaceutical Co., Ltd., the potential for further breakthroughs in his field remains promising.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile